-
-
-
-
-
-
-
Shire launches screen responsibly, an eyelove® initiative dedicated to prioritizing eye health in a screen-saturated world
-
-
-
-
-
-
-
Shire (SHPG) Says Lancet Publishes Phase 2 Results from Anti-MAdCAM Antibody Showing Increased Remission Rates in Patients with Moderate-to-Severe UC
-
-
-
-
-
-
-
Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
-
-
-
-
-
-
-
Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura
-
-
-
-
-
-
-
New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease
-
-
-
-
-
-
-
U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD
-
-
-
-
-
-
-
Shire (SHPG) Announces U.S. Launch of CUVITRU
-
1,155,356 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

